# Study to Assess Safety, Tolerability and Pharmacokinetics of XC221 in Healthy Volunteers

> **NCT03459391** · PHASE1 · COMPLETED · sponsor: **PHARMENTERPRISES LLC** · enrollment: 32 (actual)

## Conditions studied

- Influenza
- Acute Respiratory Infection

## Interventions

- **DRUG:** XC221 60 mg
- **DRUG:** XC221 200 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03459391
- **Lead sponsor:** PHARMENTERPRISES LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-22
- **Primary completion:** 2017-09-26
- **Final completion:** 2017-09-26
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2018-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03459391

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03459391, "Study to Assess Safety, Tolerability and Pharmacokinetics of XC221 in Healthy Volunteers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03459391. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*